Helius Medical TechnologiesHSDT
HSDT
About: Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
Employees: 21
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
110.19% more ownership
Funds ownership: 3.31% [Q1] → 113.5% (+110.19%) [Q2]
32% more capital invested
Capital invested by funds: $81.3K [Q1] → $108K (+$26.2K) [Q2]
7% less funds holding
Funds holding: 14 [Q1] → 13 (-1) [Q2]
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for HSDT.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation.
Neutral
GlobeNewsWire
1 month ago
Helius Medical Technologies, Inc. Compliant with Nasdaq's Continued Listing Requirements
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the “Panel”) indicating that Helius has evidenced compliance with the equity requirement in Listing Rule 5550(b)(1) (the “Equity Rule”) for continued listing on the Nasdaq Capital Market.
Negative
Benzinga
1 month ago
Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Neutral
GlobeNewsWire
1 month ago
Helius Medical Technologies Announces Reverse Stock Split
NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on June 30, 2025. Beginning on July 1, 2025, the Company's common stock will trade on The Nasdaq Capital Market on a split adjusted basis.
Neutral
GlobeNewsWire
2 months ago
Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device
- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160- NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an additional authorized claim for payment for the PoNS Device from CignaHealth.
Neutral
GlobeNewsWire
2 months ago
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis-
Neutral
GlobeNewsWire
2 months ago
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement-
Neutral
GlobeNewsWire
2 months ago
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering
NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants.
Neutral
GlobeNewsWire
2 months ago
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement
Neutral
GlobeNewsWire
3 months ago
Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting
Shepherd Center's Dr. Deborah Backus to Showcase Final Results of PoNSTEP Study, Providing New Insight into Maximizing Impact of Neuromodulation to Improve Gait in People with MS Shepherd Center's Dr. Deborah Backus to Showcase Final Results of PoNSTEP Study, Providing New Insight into Maximizing Impact of Neuromodulation to Improve Gait in People with MS
Charts implemented using Lightweight Charts™